Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

HAVN Life Sciences Inc

Healthcare US HAVLF

0.0001USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.0080.10
LowHigh

Fundamentals

  • Previous Close 0.0001
  • Market Cap0.33M
  • Volume22105
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.50264M
  • Revenue TTM0.59M
  • Revenue Per Share TTM0.08
  • Gross Profit TTM 0.09M
  • Diluted EPS TTM-2.32

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-04-30 2021-04-30 2020-04-30
Type yearly yearly yearly
Date 2022-04-30 2021-04-30 2020-04-30
Income before tax -22.44355M -30.38063M -0.04058M
Minority interest - - -
Net income -22.44355M -30.38063M -0.04058M
Selling general administrative 8.46M 19.08M 0.04M
Selling and marketing expenses 0.21M 0.33M -
Gross profit 0.09M - -
Reconciled depreciation 0.58M 4.60M 0.00000M
Ebit -9.78047M -24.34569M -0.49349M
Ebitda -9.20485M -19.74116M -0.04058M
Depreciation and amortization 0.58M 4.60M -
Non operating income net other - - -
Operating income -9.81047M -24.34569M -0.04058M
Other operating expenses 10.09M 24.35M 0.04M
Interest expense 0.06M 0.02M 0.00000M
Tax provision - - -
Interest income 0.03M 0.00000M 0.00055M
Net interest income -0.03414M -0.01750M 0.00055M
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense 0.06M 0.02M -
Total revenue 0.28M 0.00000M 0.00000M
Total operating expenses 9.90M 24.35M 0.04M
Cost of revenue 0.19M - -
Total other income expense net -12.59894M -6.01744M -
Discontinued operations - - -
Net income from continuing ops -22.44355M -30.38063M -0.04058M
Net income applicable to common shares -22.44355M -30.38063M -0.48691M
Preferred stock and other adjustments - - -
Breakdown 2022-04-30 2021-04-30 2020-04-30
Type yearly yearly yearly
Date 2022-04-30 2021-04-30 2020-04-30
Total assets 4.06M 14.24M 1.94M
Intangible assets 0.93M - -
Earning assets - - -
Other current assets 0.22M - -
Total liab 0.92M 1.04M 0.04M
Total stockholder equity 3.14M 13.20M 1.90M
Deferred long term liab - - -
Other current liab 0.21M 0.58M -
Common stock 49.15M 37.00M 1.92M
Capital stock 49.15M 37.00M 1.92M
Retained earnings -52.86476M -30.42121M -0.04058M
Other liab - - -
Good will - - -
Other assets 0.02M 0.02M -
Cash 1.06M 9.40M 1.62M
Cash and equivalents - - -
Total current liabilities 0.61M 0.71M 0.04M
Current deferred revenue - - -
Net debt -0.66630M -8.94534M -1.61698M
Short term debt 0.08M 0.13M -
Short long term debt - - -
Short long term debt total 0.39M 0.46M -
Other stockholder equity 6.85M 6.62M 0.02M
Property plant equipment 0.36M 0.68M -
Total current assets 2.75M 10.61M 1.94M
Long term investments - - -
Net tangible assets 2.21M 10.27M 1.90M
Short term investments - - -
Net receivables 0.32M 0.21M 0.25M
Long term debt - - -
Inventory 1.15M 0.36M -
Accounts payable 0.32M 0.53M 0.04M
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income - - -
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other 0.02M 0.02M -
Deferred long term asset charges - - -
Non current assets total 1.31M 3.63M 0.00000M
Capital lease obligations 0.39M 0.46M -
Long term debt total - - -
Breakdown 2022-04-30 2021-04-30 2020-04-30
Type yearly yearly yearly
Date 2022-04-30 2021-04-30 2020-04-30
Investments -2.03074M -0.39670M -0.25000M
Change to liabilities -0.05493M 0.51M 0.49M
Total cashflows from investing activities -2.03074M -0.39670M -3.00000M
Net borrowings -0.13095M -0.03274M -0.03274M
Total cash from financing activities 1.56M 18.60M 1.94M
Change to operating activities -0.37221M -0.91997M -0.90000M
Net income -22.44355M -30.38063M -0.04058M
Change in cash -8.34602M 7.78M 1.62M
Begin period cash flow 9.40M 1.62M -0.00009M
End period cash flow 1.06M 9.40M 1.62M
Total cash from operating activities -7.87506M -10.42200M -0.07501M
Issuance of capital stock 2.00M 14.13M 1.92M
Depreciation 0.58M 4.60M 4.60M
Other cashflows from investing activities -0.75567M -0.01803M -3.00000M
Dividends paid - - -
Change to inventory - - -
Change to account receivables -0.10907M -0.20679M -0.20679M
Sale purchase of stock - - -
Other cashflows from financing activities -0.30902M 4.50M 0.02M
Change to netincome 14.53M 15.97M -0.00658M
Capital expenditures 0.10M 0.03M 0.03M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital -0.53620M -0.61506M -0.03389M
Stock based compensation 1.79M 9.14M -
Other non cash items 12.74M 6.83M -0.00055M
Free cash flow -7.97813M -10.45461M -0.07501M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
HAVLF
HAVN Life Sciences Inc		 - -% 0.0001 - - 0.56 0.31 0.58 -0.0219
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.

HAVN Life Sciences Inc

22071 Fraserwood Way, Richmond, BC, Canada, V6W 1J5

Key Executives

Name Title Year Born
Mr. Tim Moore Interim CFO, CEO & Chairman 1958
Ms. Jenna Pozar Chief Operations Officer NA
Mr. Paul More Controller NA
Mr. Tim Moore Interim CFO, CEO & Chairman 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions